Jane Street Group LLC Has $34,000 Stake in Allakos Inc. (NASDAQ:ALLK)

Jane Street Group LLC lowered its position in Allakos Inc. (NASDAQ:ALLK) by 71.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 52,495 shares of the company’s stock after selling 128,917 shares during the period. Jane Street Group LLC owned 0.06% of Allakos worth $34,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. RBF Capital LLC increased its stake in shares of Allakos by 45.9% during the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after purchasing an additional 160,529 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Allakos in the third quarter worth $1,143,000. FMR LLC boosted its holdings in Allakos by 14.6% in the third quarter. FMR LLC now owns 5,370,247 shares of the company’s stock worth $3,508,000 after purchasing an additional 685,623 shares in the last quarter. GSA Capital Partners LLP increased its position in Allakos by 11.9% during the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after buying an additional 84,750 shares during the last quarter. Finally, Point72 DIFC Ltd bought a new position in Allakos during the second quarter valued at about $25,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analysts Set New Price Targets

Separately, JMP Securities reissued a “market outperform” rating and set a $3.00 price objective on shares of Allakos in a report on Thursday, September 26th.

Allakos Trading Up 4.9 %

NASDAQ ALLK opened at $0.91 on Friday. Allakos Inc. has a 1 year low of $0.54 and a 1 year high of $1.69. The company has a fifty day simple moving average of $1.10 and a 200 day simple moving average of $0.90. The company has a market cap of $81.30 million, a P/E ratio of -0.45 and a beta of 0.86.

Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. Equities research analysts forecast that Allakos Inc. will post -1.16 EPS for the current fiscal year.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.